ArticleBMC complementary medicine and therapies2025
GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Digestive-Enzyme Inhibition and Antiglycation Activity ofCurrent issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) remains a global health burden characterized by insulin resistance, persistent hyperglycaemia, and chronic inflammation. Although single-target therapies effectively reduce glucose levels, they seldom address oxidative stress or adipocyte dysfunction. Polyherbal formulations (PHFs) harness synergistic phytochemicals for multimodal intervention; however, many lack mechanistic transparency owing to excessive inclusion of diverse botanical bioactives, suffer from non-standardized composition, and underexplore volatile antidiabetic constituents. Confronting these challenges, we developed Gluco Balance V (GB5), a cold-percolated ethanolic extract comprising equal proportions of bio-effective parts of Asparagus racemosus, Cyperus rotundus, Tinospora cordifolia, Terminalia arjuna, and Mimosa pudica. These botanicals were selected for complementary antidiabetic, antioxidant, and adiporegulatory activities documented in preclinical and clinical settings, indicating balanced, synergistic, and safe bioactivity.
methodsGB5's phytochemical composition was standardized using gas chromatography-mass spectrometry (GC-MS) fingerprinting. In vitro assays assessed 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO) scavenging capacity, inhibition of carbohydrate-digesting enzymes (α-amylase, α-glucosidase), enzyme kinetics, and effects on glucose uptake (GU) and lipid accumulation (LA) in yeast and 3T3-L1 adipocytes. Computational network pharmacology, molecular docking, and pharmacokinetic analyses elucidated molecular targets and bioavailability. Statistical analyses employed robust dose-response modelling, analysis of variance with Dunnett's T3 test, and t-tests with false discovery rate correction.
resultsGC-MS identified 21 bioactive compounds, including phytol, fatty acids, and sterols, driving GB5's therapeutic synergy. GB5 showed robust antioxidant activity (DPPH and NO; half-maximal inhibitory concentration (IC
conclusionsGB5's multi-targeted efficacy against hyperglycaemia, oxidative stress, and adipocyte dysfunction positions it as a promising complementary therapy for T2DM, meriting further in vivo evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.